ArticleEuropean journal of clinical pharmacology2025
Secukinumab improves pregnancy outcomes in recurrent spontaneous abortion with T helper 17 cells/T regulatory cells imbalance: a retrospective cohort study.
Article in European journal of clinical pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectiveThis study aimed to evaluate the efficacy and safety of secukinumab, an Interleukin-17A (IL-17A) inhibitor, in patients with recurrent spontaneous abortion (RSA) associated with T helper 17 cells / T regulatory cells (Th17/Treg) imbalance.
methodsThis retrospective cohort study evaluated 108 RSA patients with confirmed Th17/Treg imbalance (Th17/Treg ≥ 0.6 or IL-17A > 4.74 pg/mL) at a single center. Patients were divided into secukinumab (n = 54; 3 mg/kg subcutaneously plus standard therapy) and control (n = 54; standard therapy alone) groups. Primary outcomes included live birth rate and immunological parameters (Th17/Treg ratio, IL-17A levels), with secondary assessments of neonatal outcomes and safety.
resultsThe secukinumab group demonstrated significantly higher live birth rates (83.33% [45/54] vs 64.81% [35/54]; P = 0.047), with an odds ratio (OR) of 2.71 (95% Confidence Interval (CI): 1.10-6.73), and greater reductions in Th17/Treg ratios (P = 0.010) and IL-17A levels (P = 0.001) compared to controls. No congenital anomalies, maternal or neonatal infections, or treatment-related serious adverse events were observed in either group.
conclusionFor RSA characterized by Th17/Treg imbalance, secukinumab demonstrates both clinical efficacy and an acceptable safety profile, suggesting its therapeutic utility.
Indexed as
Identifiers
41428078What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.